Stay updated with breaking news from Stem Cell Transplant Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Food and Drug Administration on December 15 approved the first-ever drug to be used for the prevention of acute graft versus host disease (aGVHD) in adult and pediatric patients, opening the door for safer bone marrow and blood stem cell transplants in patients who do not have a perfectly matched graft donor.
The Food and Drug Administration on December 15 approved the first-ever drug to be used for the prevention of acute graft versus host disease (aGVHD
Large Gene panel helpful in identifying cancer-causing genes ANI | Updated: Feb 06, 2021 14:14 IST Washington [US], February 6 (ANI): Researchers during a recent study have found a gene panel that includes all genes known to potentially cause cancer. This can be readily adopted for use in clinical laboratories to diagnose acute myeloid leukemia, or AML. The 523-gene panel, which looks about 10 times the number of cancer-causing genes, developed by San Diego-based biotech company Illumina, is currently used to diagnose and fine-tune treatment for a variety...
Credit: Kim Ratliff, Augusta University Photographer AUGUSTA, Ga. (Feb. 1, 2020) - A gene panel that looks for about 10 times the number of cancer-causing genes as panels currently used to diagnose and fine tune treatment for a variety of cancers is effective at identifying problematic genes in the most common leukemia, investigators report. The 523-gene panel, developed by San Diego-based biotech company Illumina, which includes all genes known to potentially cause cancer, can be readily adopted for use in clinical laboratories to diagnose acute myeloid leukemia, or AML, the investigators r...
Dr. Han Myint Appointed as NextCure’s Chief Medical Officer January 14, 2021 16:05 ET | Source: NextCure NextCure Beltsville, Maryland, UNITED STATES BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key product...